Everything we can document is documented.
Where the product comes from, chain of distribution, how the price is quoted.
We would rather be trusted than simply believed.
A patient considering an investigational treatment that insurance will not cover is doing something reasonable: reading everything, discounting anything that sounds like marketing, and looking for the clinic who is willing to state its limits.
These treatments are investigational. The trial base for many chronic conditions is early, response varies between individuals, and there are patients for whom the physician will recommend against proceeding.
What the clinic can control is the provenance of the product, the qualifications of the person administering it, the clarity of the protocol, and the seriousness of the follow-up.
From donated cord to administration.
6 documented stages. Ask to review the lot-specific record at any point before consent.
Donation
Consented donation following live birth
Umbilical cord tissue and cord blood are donated with informed maternal consent. No embryonic tissue is used in any protocol offered by the practice.
Screening
Donor eligibility screening
Donor eligibility and infectious-disease testing are performed under applicable human-cell and tissue requirements and laboratory standards.
Processing
Prepared by an independent laboratory
The product is prepared at an FDA-registered, AATB-accredited facility. The clinic is not the processor, preserving a meaningful separation between manufacturing and treatment.
Verification
Count and viability documented before release
Lot-specific identity, count, and viability documentation accompany the product rather than relying on a generic brochure average.
Transit
Scheduled overnight cold chain
Product ships against the treatment date directly to the physician. It is not warehoused at the clinic or carried over between patient protocols.
Administration
Reviewed before consent and administered by the physician
Lot documentation is reviewed with the patient before administration and retained in the clinical record.
4 preparations, selected by protocol.
Cord blood-derived mesenchymal cells
Considered for systemic intravenous protocols where the treatment objective is not confined to a single joint or structure.
Wharton’s jelly mesenchymal cells
Used in certain systemic protocols and localized applications, including coordinated image-guided joint treatment.
Wharton’s jelly tissue complex
Considered in selected orthopedic applications where the structural matrix is relevant to the intended use.
Exosome preparations
Discussed adjunctively in specific protocols, with a clear explanation of what is established and what remains uncertain.
Three questions before recommending anything.
Can the medical condition be improved with stem cell therapy?
Disease stage, overall health, and preferred route of administration is discussed upfront.
What other therapies are available which can be used with, or in liu of regenerative medicine?
This clinic offers a wide variety of medical therapies which complement the stem cell treatment.
What would count as a result, and how long does it take?
Variables that affect the outcome, along with your healing timeline are discussed upfront.
Who we may decline to treat.
Common reasons include an active malignancy, acute infection, an unmanaged condition that should be stabilized first, a conventional pathway with stronger evidence that has not been tried, structural damage beyond what a regenerative approach can plausibly affect, or expectations that remain unrealistic after discussion.
Where the physician declines, the reasoning is explained and—where possible—the patient is directed toward a better-placed specialist or pathway.
Bring your questions. Bring your records.
An evaluation with the physician, ending in a direct answer about candidacy.